NEWS

Filter Releases
 
News
Date Title and Summary View
Aug 1, 2016
FREMONT, Calif., Aug. 1, 2016 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced that it will report second quarter 2016 financial results after market close on Monday, August 8, 2016. Following the announcement, the Ardelyx management team ...
Aug 1, 2016
FREMONT, Calif., Aug. 1, 2016 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for its composition of matter patent application (U.S. Patent Applic...
Jul 15, 2016
FREMONT, Calif., July 15, 2016 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced that it has entered into an agreement to sell shares of its common stock for aggregate gross proceeds of approximately $110 million in a private placement. Inv...
Jun 22, 2016
FREMONT, Calif., June 22, 2016 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced updates to two of the Company's ongoing development programs. Ardelyx today announced that, based on the positive outcome of a recent End-of-Phase 2...
Jun 7, 2016
FREMONT, Calif., June 7, 2016 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced that Robert Bazemore joined the Company's Board of Directors.  Mr. Bazemore, who currently serves as President and Chief Executive Officer of Epizyme, Inc., bri...
Jun 3, 2016
FREMONT, Calif., June 3, 2016 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced that Jeremy S. Caldwell, Ph.D., Executive Vice President and Chief Scientific Officer, will present an overview of the Company during the 2016 BIO International...
May 9, 2016
FREMONT, Calif., May 9, 2016 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced financial results for the first quarter ended March 31, 2016. "We are very pleased with the progress we have made thus far in 2016," said Mike Raab, P...
May 2, 2016
FREMONT, Calif., May 2, 2016 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced that it will report first quarter 2016 financial results Monday, May 9, 2016 after the close of the market. Following the announcement, the Ardelyx management te...
Mar 4, 2016
FREMONT, Calif., March 4, 2016 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced financial results for the fourth quarter and full-year ended December 31, 2015. "2015 was an exceptional year for Ardelyx, highlighted by the advanc...
Feb 25, 2016
FREMONT, Calif., Feb. 25, 2016 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2015, on Friday, March 4, 2016. Following the announcement, t...
Feb 2, 2016
FREMONT, Calif., Feb. 2, 2016 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and renal diseases, today announced that Mike Raab, President and Chief Executive Officer, and David Rosenbaum, Ph.D., Senior Vice President of Drug Development, will participate in the 2016 Leerink Part...
Jan 13, 2016
FREMONT, Calif., Jan. 13, 2016 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced the completion of its previously announced underwritten public offering of 8,625,000 shares of its common stock at a public offering price of $10.00 per share,...
Jan 7, 2016
FREMONT, Calif., Jan. 7, 2016 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced the pricing of an underwritten public offering of 7,500,000 shares of its common stock at a public offering price of $10.00 per share, before underwriting disco...
Jan 6, 2016
FREMONT, Calif., Jan. 6, 2016 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced that it has commenced an underwritten public offering of up to $75,000,000 of shares of its common stock. All of the shares to be sold in the offering will be o...
Jan 5, 2016
FREMONT, Calif., Jan. 5, 2016 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced positive results of an open label clinical study evaluating the pharmacodynamic (PD) activity of RDX022 in healthy adult volunteers. The study demonstrated that...
= add release to Briefcase

RESOURCES